Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

• ClinicalTrials.gov Identifier: NCT02922777
• Recruitment Status: Recruiting
• First Posted: October 4, 2016
• Last Update Posted: March 22, 2021
• Sponsor: University of Texas Southwestern Medical Center
• Collaborators: Texas Tech University Health Sciences Center; BerGenBio ASA
• Information provided by (Responsible Party): University of Texas Southwestern Medical Center

Study Description

Brief Summary:

This study is being done to evaluate the safety of the investigational study drug, BGB324 when administered in combination with docetaxel, and to establish the maximum tolerated dose.

Condition or disease	Intervention/treatment	Phase
Non-Small Cell Lung Carcinoma	Drug: BGB324; Drug: Docetaxel	Phase 1

Detailed Description:

Lung cancer remains the leading cause of cancer-related deaths worldwide with an estimated incidence of 1.6 million cases resulting in 1.4 million deaths in annually. Non-small-cell lung cancer (NSCLC) represents 80-85% of cases, and adenocarcinoma is the most common histology.2 The majority of NSCLC patients present with advanced or metastatic disease that is not amenable to surgical resection. Platinum-based combination chemotherapy has reached a therapeutic plateau with a median overall survival (OS) of 7.4 to 9.9 months.

BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor that is over-expressed in many metastatic solid tumors and has been identified as a marker of a poor prognosis in patients with non-small cell lung cancer (NSCLC).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 30 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
• Actual Study Start Date: November 2016
• Estimated Primary Completion Date: May 2022
• Estimated Study Completion Date: May 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: BGB324 in combination with docetaxel; The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.	Drug: BGB324; 75 mg/m2 every 21 days; Drug: Docetaxel; 75 mg/m2 given IV every 21 days; Other Name: Taxotere

Outcome Measures

Primary Outcome Measures :

1. Determine the maximum tolerated dose of BGB324 in combination with docetaxel [ Time Frame: 42 days or 2 cycles of 21 days ]
   Determine and recommended the Phase 2 dose of BGB324 administered with the standard dose of docetaxel in patients in NSCLC by pharmacodynamics and pharmacokinetic assessments.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

A patient is eligible for the study if the following criteria are met:

1. Provision of written informed consent to participate in this investigational study
2. Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] Staging manual) NSCLC
3. Up to three previous lines of therapy, of which one must have been a platinum-based doublet therapy and no more than two were cytotoxic chemotherapy.
4. Radiographic disease recurrence or progression during or after the last line of chemotherapy
5. Patients with known activating EGFR mutations or ALK rearrangements should have progressed after appropriate targeted treatment in addition to progressing during or after platinum-based doublet chemotherapy
6. European Cooperative Oncology Group (ECOG) performance status 0 or 1
7. Age 18 years or older
8. Measurable or evaluable disease according to RECIST v1.1
9. Previously treated brain metastases (surgery and/or radiation therapy) are eligible, provided that patients are asymptomatic and not requiring corticosteroids

10. The following minimum intervals are required between prior treatment and initiation of study therapy:

    Cytotoxic chemotherapy: 3 weeks Molecularly targeted therapy or immunotherapy: 2 weeks Conventional fractionated radiation therapy: 2 weeks Stereotactic radiation therapy: 1 week Major surgery: 3 weeks

11. Adequate hematologic function (absolute neutrophil count [ANC] ≥ 1500 cells/µL; hemoglobin ≥ 9 g/dL; platelets ≥ 100,000/µL
12. Adequate renal function (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation)
13. Adequate hepatic function: total bilirubin ≤ upper limit of normal [ULN], alanine aminotransferase [ALT] ≤ 1.5 x ULN, aspartate aminotransferase [AST] ≤ 1.5 x ULN). ALT and AST ≤ 5x ULN if documented liver metastases
14. Previous treatment-associated toxicities resolved to CTCAE grade ≤2 (except alopecia)
15. Adequate archival tissue (10-15 slides, or 5 slides with 3 sections per slide) for biomarker analysis

16. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to taking their first dose of BGB324. Male patients and female patients of reproductive potential must agree to practice highly effective methods of contraception (such as hormonal implants, combined oral contraceptives, injectable contraceptives, intrauterine device with hormone spirals, total sexual abstinence, vasectomy) throughout the study and for ≥3 months after the last dose of BGB324. Female patients are considered NOT of childbearing potential if they have a history of surgical sterility, including tubal ligation, or evidence of post-menopausal status defined as any of the following:

    • Natural menopause with last menses >1 year ago
    • Radiation induced oophorectomy with last menses >1 year ago
    • Chemotherapy induced menopause with last menses >1 year ago

Exclusion Criteria

A patient is excluded from the study if any of the following criteria are met:

1. Pregnant or lactating
2. Abnormal left ventricular ejection fraction on echocardiography (less than the lower limit of normal for a patient of that age at the treating institution or <45%)
3. History of an ischemic cardiac event including myocardial infarction within 3 months of study entry
4. NSCLC with evidence of a centrally cavitating lesion
5. Peripheral neuropathy NCI CTCAE ≥Grade 2 at baseline
6. Pulmonary hemorrhage or hemoptysis > 2.5 mL blood within 6 weeks (or within 2 weeks if source definitively treated [eg, radiation therapy or bronchoscopic procedure])
7. Congestive cardiac failure of >Grade 2 severity according to the NYHA defined as symptomatic at less than ordinary levels of activity
8. Unstable cardiac disease, including unstable angina or unstable hypertension, as defined by the need for change in medication for lack of disease control within the last three months
9. History or presence of sustained bradycardia (less than or equal to 60 BPM) or history of symptomatic bradycardia, left bundle branch block, cardiac pacemaker or significant atrial tachyarrhythmias , as defined by the need for treatment
10. Previous treatment with docetaxel or an Axl inhibitor
11. Current treatment with agents that may prolong QT interval and may cause Torsade de Points which cannot be discontinued at least five half-lives prior to treatment. Please see Appendix J for list of relevant medications
12. Known family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy
13. Previous history of Grade 3 or worse drug-induced QTc prolongation requiring treatment withdrawal
14. Screening 12-lead ECG with a measurable QTc interval according to Fridericia's correction >450 ms
15. Ongoing infection requiring systemic treatment
16. Inability to tolerate oral medication

17. Impaired coagulation as evidenced by:

    • INR >1.5 times ULN, or
    • aPTT > 1.5 times ULN
18. Clinically active existing gastrointestinal disease affecting drug absorption, such as celiac disease or Crohn's disease
19. Previous bowel resection anticipated to affect drug absorption
20. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
21. Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index
22. Active, uncontrolled central nervous system (CNS) disease
23. Known active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required)
24. Major surgery within 28 days prior to the start of BGB324, excluding skin biopsies and procedures for insertion of central venous access devices

Contacts and Locations

Contacts

Contact: Joyce Bolluyt, RN; 214-648-7097; joyce.bolluyt@utsouthwestern.edu

Locations

United States, Texas

University of Texas Southwestern Medical Center; Recruiting

Dallas, Texas, United States, 75063

Contact: Joyce Bolluyt, RN 214-648-7097 joyce.bolluyt@utsouthwestern.edu

Covenant Health Systems/Joe Arrington Cancer Treatment and Research Center; Not yet recruiting

Lubbock, Texas, United States, 79410

Contact: Donald P Quick, MD 806-725-8000 dquick@covhs.org

Sub-Investigator: Donald P Quick, MD

Sponsors and Collaborators

University of Texas Southwestern Medical Center

Texas Tech University Health Sciences Center

BerGenBio ASA

Investigators

• Principal Investigator: David E Gerber, MD; University of Texas Southwestern Medical Center

More Information

• Responsible Party: University of Texas Southwestern Medical Center
• ClinicalTrials.gov Identifier: NCT02922777
• Other Study ID Numbers: STU 052015-077
• First Posted: October 4, 2016
• Last Update Posted: March 22, 2021
• Last Verified: March 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Carcinoma, Non-Small-Cell Lung; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Docetaxel; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action